226908-75-4Relevant academic research and scientific papers
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
-
Page/Page column 45, (2008/06/13)
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.
Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities
Kurimoto, Ayumu,Ogino, Tetsuhiro,Ichii, Shinji,Isobe, Yoshiaki,Tobe, Masanori,Ogita, Haruhisa,Takaku, Haruo,Sajiki, Hironao,Hirota, Kosaku,Kawakami, Hajime
, p. 1091 - 1099 (2007/10/03)
In order to create novel compounds which possess potent interferon (IFN) inducing activities with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various alkoxy or alkylthio moieties at the adenine C(2)-position, were synthesiz
Heterocyclic compounds
-
, (2008/06/13)
The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or —NR3— (R3may form a heterocyclic ring or a substituted heterocyclic ring with R1via the nitrogen atom), R1is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.
